FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170331034> ?p ?o ?g. }

• W2170331034 endingPage "159" @default.
• W2170331034 startingPage "150" @default.
• W2170331034 abstract "Abstract Learning Objectives After completing this course, the reader will be able to: Describe three regimens that use mitoxantrone in indolent lymphoma. List the NCCN-recommended regimens for the first-line treatment of follicular lymphoma. Discuss the side-effect profile of mitoxantrone in combination with other agents for indolent lymphoma. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com With the introduction of newer therapeutic approaches, survival in indolent non-Hodgkin's lymphoma (NHL) appears to be improving. Mitoxantrone (Novantrone®; Serono, Inc.; Rockland, MA, http://www.seronousa.com), an anthracenedione with low cardiotoxic potential, has demonstrated activity in indolent NHL in combination with fludarabine (Fludara®; Berlex Laboratories; Wayne, NJ, http://www.berlex.com) and other agents. In a Southwest Oncology Group trial (SWOG 9501), treatment with fludarabine and mitoxantrone (FM) induced a complete remission (CR) rate of 44% and a partial remission (PR) rate of 50% in untreated patients. The estimated 4-year progression-free survival (PFS) rate was 38%. In a multicenter Italian trial comparing the efficacy of FM with that of cyclophosphamide, doxorubicin (Adriamycin®; Bedford Laboratories; Bedford, OH, http://www.bedfordlabs.com), vincristine (Oncovin®; Eli Lilly and Company; Indianapolis, IN, http://www.lilly.com), and prednisone (Deltasone®; Pfizer Pharmaceuticals; New York, NY, http://www.pfizer.com), CHOP, followed by rituximab (Rituxan®; Genentech, Inc.; South San Francisco, CA, http://www.gene.com) for patients with incomplete clinical or molecular responses, the CR and molecular response rates were significantly higher in the FM arm, but the PFS and overall survival (OS) rates did not differ between the two arms. However, FM was also significantly less toxic than CHOP. The administration of rituximab following chemotherapy resulted in higher clinical and molecular response rates in both arms. In a separate trial, FM plus dexamethasone (Decadron®; Merck and Co., Inc.; Whitehouse Station, NJ, http://www.merck.com), FND, plus concurrent rituximab produced a CR rate of 92%. In a randomized German study, patients with indolent lymphomas received FM plus cyclophosphamide (FCM) or FCM with rituximab. PFS and OS times were significantly better for patients who received combined chemoimmunotherapy. Mitoxantrone-based regimens are highly active and well tolerated in patients with both relapsed and previously untreated indolent lymphomas. The addition of rituximab appears to increase the activity of the FM, FND, and FCM regimens. Although the results of the Italian multicenter study support the superiority of FM over CHOP in terms of clinical and molecular responses and tolerability, additional studies using rituximab in combination with both of these regimens should be attempted to determine the possible further benefit of both in the management of indolent lymphoma. Because cure remains elusive in patients with indolent lymphoma, maximum prolongation of PFS with minimal toxicity and maximum preservation of quality of life should remain central goals of treatment." @default.
• W2170331034 created "2016-06-24" @default.
• W2170331034 creator A5006742031 @default.
• W2170331034 creator A5058320427 @default.
• W2170331034 creator A5060386553 @default.
• W2170331034 creator A5082720713 @default.
• W2170331034 creator A5088142456 @default.
• W2170331034 date "2005-02-01" @default.
• W2170331034 modified "2023-10-14" @default.
• W2170331034 title "The Role of Mitoxantrone in the Treatment of Indolent Lymphomas" @default.
• W2170331034 cites W1785340630 @default.
• W2170331034 cites W1830057497 @default.
• W2170331034 cites W1848698181 @default.
• W2170331034 cites W1897371354 @default.
• W2170331034 cites W1921096083 @default.
• W2170331034 cites W1982844809 @default.
• W2170331034 cites W1995586052 @default.
• W2170331034 cites W2014145299 @default.
• W2170331034 cites W2044475548 @default.
• W2170331034 cites W2101597877 @default.
• W2170331034 cites W2139942643 @default.
• W2170331034 cites W2144010959 @default.
• W2170331034 cites W2163487873 @default.
• W2170331034 cites W2165775167 @default.
• W2170331034 cites W2167635913 @default.
• W2170331034 cites W2168926834 @default.
• W2170331034 cites W2256690185 @default.
• W2170331034 cites W2278012184 @default.
• W2170331034 cites W2331799595 @default.
• W2170331034 cites W2590177563 @default.
• W2170331034 cites W2608724752 @default.
• W2170331034 cites W94899341 @default.
• W2170331034 doi "https://doi.org/10.1634/theoncologist.10-2-150" @default.
• W2170331034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15709217" @default.
• W2170331034 hasPublicationYear "2005" @default.
• W2170331034 type Work @default.
• W2170331034 sameAs 2170331034 @default.
• W2170331034 citedByCount "51" @default.
• W2170331034 countsByYear W21703310342012 @default.
• W2170331034 countsByYear W21703310342013 @default.
• W2170331034 countsByYear W21703310342014 @default.
• W2170331034 countsByYear W21703310342015 @default.
• W2170331034 countsByYear W21703310342016 @default.
• W2170331034 countsByYear W21703310342017 @default.
• W2170331034 countsByYear W21703310342018 @default.
• W2170331034 countsByYear W21703310342022 @default.
• W2170331034 countsByYear W21703310342023 @default.
• W2170331034 crossrefType "journal-article" @default.
• W2170331034 hasAuthorship W2170331034A5006742031 @default.
• W2170331034 hasAuthorship W2170331034A5058320427 @default.
• W2170331034 hasAuthorship W2170331034A5060386553 @default.
• W2170331034 hasAuthorship W2170331034A5082720713 @default.
• W2170331034 hasAuthorship W2170331034A5088142456 @default.
• W2170331034 hasConcept C126322002 @default.
• W2170331034 hasConcept C143998085 @default.
• W2170331034 hasConcept C2776694085 @default.
• W2170331034 hasConcept C2776755627 @default.
• W2170331034 hasConcept C2777058707 @default.
• W2170331034 hasConcept C2778720950 @default.
• W2170331034 hasConcept C2779263901 @default.
• W2170331034 hasConcept C2779338263 @default.
• W2170331034 hasConcept C2779429289 @default.
• W2170331034 hasConcept C2779725641 @default.
• W2170331034 hasConcept C2780653079 @default.
• W2170331034 hasConcept C2780923524 @default.
• W2170331034 hasConcept C71924100 @default.
• W2170331034 hasConceptScore W2170331034C126322002 @default.
• W2170331034 hasConceptScore W2170331034C143998085 @default.
• W2170331034 hasConceptScore W2170331034C2776694085 @default.
• W2170331034 hasConceptScore W2170331034C2776755627 @default.
• W2170331034 hasConceptScore W2170331034C2777058707 @default.
• W2170331034 hasConceptScore W2170331034C2778720950 @default.
• W2170331034 hasConceptScore W2170331034C2779263901 @default.
• W2170331034 hasConceptScore W2170331034C2779338263 @default.
• W2170331034 hasConceptScore W2170331034C2779429289 @default.
• W2170331034 hasConceptScore W2170331034C2779725641 @default.
• W2170331034 hasConceptScore W2170331034C2780653079 @default.
• W2170331034 hasConceptScore W2170331034C2780923524 @default.
• W2170331034 hasConceptScore W2170331034C71924100 @default.
• W2170331034 hasIssue "2" @default.
• W2170331034 hasLocation W21703310341 @default.
• W2170331034 hasLocation W21703310342 @default.
• W2170331034 hasOpenAccess W2170331034 @default.
• W2170331034 hasPrimaryLocation W21703310341 @default.
• W2170331034 hasRelatedWork W2058154950 @default.
• W2170331034 hasRelatedWork W2112679438 @default.
• W2170331034 hasRelatedWork W2133023691 @default.
• W2170331034 hasRelatedWork W2165775167 @default.
• W2170331034 hasRelatedWork W2318073446 @default.
• W2170331034 hasRelatedWork W2935716814 @default.
• W2170331034 hasRelatedWork W2943976784 @default.
• W2170331034 hasRelatedWork W4236815493 @default.
• W2170331034 hasRelatedWork W4244051174 @default.
• W2170331034 hasRelatedWork W4250500771 @default.
• W2170331034 hasVolume "10" @default.
• W2170331034 isParatext "false" @default.
• W2170331034 isRetracted "false" @default.
• W2170331034 magId "2170331034" @default.

• next